In Brief: SmithKline penciclovir I.V.
Executive Summary
SmithKline penciclovir I.V.: SB discloses the May filing of an NDA for I.V. penciclovir for the treatment of mucocutaneous herpes simplex and herpes zoster infections in immunocompromised patients. SB markets oral penciclovir as Denavir for herpes labialis...